ATAI Life Sciences Inc.
NASADAQ: ATAI
Company Overview
atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
The company's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders.
atai is headquartered in Berlin, with offices in New York.
Financial Highlights
$20,376,000
Revenue (ttm)
$20,376,000
Gross Profit (ttm)
-$1.21
Diluted EPS (ttm)
Management Team
Mr. Christian Angermayer
Founder & Chairman of the Supervisory Board
Mr. Florian Brand
Co-Founder, MD & CEO
Dr. Srinivas G. Rao M.D., Ph.D.
Co-Founder & Chief Scientific Officer
Dr. Rolando Gutierrez-Esteinou M.D.
Chief Medical Officer
Mr. Lars Christian Wilde
Co-Founder
Mr. Gregory L. Weaver CPA, M.B.A.
MD & CFO
Mr. Frank Stegert
VP of Investment Management
Ms. Madison Crawford
Sr. Mang. of Accounting
Mr. Ryan Barrett
VP of Corp. Devel., Gen. Counsel & Company Sec.
Ms. Anna Richardson
VP of People & Culture
Key Highlights
Market Capitalization
$0
Shares Outstanding
0
Shares Short (% of Float)
()
Insider Ownership
9%